XTRA:BAYNPharmaceuticals
Assessing Bayer (XTRA:BAYN) Valuation After Weak Earnings And Cautious Guidance Trigger Share Price Slide
Why Bayer’s latest earnings triggered a sharp market reaction
Bayer (XTRA:BAYN) came under pressure after reporting a full year 2025 net loss of €3,620 million, weaker than the prior year, alongside cautious 2026 guidance that pointed to modest sales and earnings expectations.
The company now forecasts 2026 net sales of €45 billion to €47 billion at constant currencies, with core earnings per share between €4.30 and €4.80, a range investors are weighing against recent profitability...